NCT06460987Completed
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA
Source: ClinicalTrials.gov · Last updated 14 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 245 (actual)
- First submitted
- 28 May 2024
- Start date
- 1 Dec 2022
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Diseases
- IgA nephropathy
- NCT number
- NCT06460987
What you commit to
- Study type: Observational
- Participants enrolled: 245
- From 1 Dec 2022 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous renal transplantation;
Other illness
- autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease, lupus nephritis, lupus nephritis,;
Lab values
- chronic hepatic disease, malignant tumor, active malignancy, heart failure with ejection fraction \<40%;
Other
- secondary IgAN;
- followed up less than 6 months;
Who the study is looking for
- primary IgAN diagnosed by renal biopsy;
- receive RASI inhibitors for at least 3 months;
- serum potassium \<5 mmol/L;
- protein-to-creatinine ratio (PCR) \>0.3 mg/g
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy Coordinator of this site? Confirm its status | Yiwu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.